BACK

Allen Lefkowitz

Allen Lefkowitz

Managing Director

New York Office  |  allen.lefkowitz@torreya.com   |   212.257.5823

Allen Lefkowitz, Managing Director, leads Torreya’s Generic Pharmaceuticals Advisory team.

Allen has more than 20 years of business development, finance, and operating experience in life sciences. Having served in senior positions at the leading generics companies worldwide, he has worked on some of the largest transactions in the sector, including Sandoz’s landmark $1.5 billion acquisition of Fougera and Teva’s $3.4 billion acquisition of Sicor.

Before joining Torreya in 2013, Allen was Vice President of Business Development and Licensing at Sandoz USA, where he directed all generic and brand product licensing, as well as product and company acquisition activities. Previously, he spent nearly two decades at Teva in Israel and in the US, where he held positions in corporate and generics. He also served as global CFO of commercial operations for Teva API. He began his career at Schering-Plough.

Allen received his B.S. in economics and an M.B.A in finance/international business from New York University’s Stern School of Business. He is fluent in Hebrew.

Selected Transactions

Alphora Research
Sale of company to
Eurofins Scientific
Undisclosed
June 2017
VistaPharm
Company sale to
Warburg Pincus
$100+ million
December 2015
IGI Laboratories
Acquisition of
Alveda Pharmaceuticals
CAD $47 million
October 2015
Teva
Sale of abbreviated
new drug application
portfolio to
ANI Pharmaceuticals
$25 million +
profit share
July 2015
Sandoz
Divestiture of
certain abbreviated
new drug applications to
IDT Australia
Up to $18 million
October 2014
Sandoz
Sale of OTC
portfolio to
PLD
Undisclosed
December 2017
Crown Laboratories
Sale of
majority equity stake to
Hildred
Undisclosed
December 2017
Sandoz
Sale of
generics portfolio to
FosunPharma
$18 million
August 2017
Essential Pharmaceuticals
Asset sale to
Accord
Undisclosed
July 2017
Sandoz
Sale of selected
generic brands to
Samara Capital
Undisclosed
June 2017
Sandoz
Sale of India women's health business to
Torrent Pharma
Undisclosed
April 2017
Rubicon Research
Sale of equity stake to
Everstone Group
$33 million
November 2016
Topix Pharmaceuticals
Sale of majority stake to
New Mountain Capital
Undisclosed
July 2016
Hikma Pharmaceuticals
Sale of abbreviated
new drug applications
Undisclosed
Undisclosed
February 2016
H2-Pharma
Sale of assets to
ANI Pharmaceuticals
$10 million
February 2016
Amerigen
Senior term loan
Undisclosed
$15 million
December 2015
Crown Laboratories
Debt financing from
Hayfin Advisors
$20 million
September 2015
Sandoz
Sale of
Zonalon® to
Renaissance Pharma
Undisclosed
March 2015
Teva
Sale of 31 abbreviated
new drug applications to
ANI Pharmaceuticals
$12.5 million +
profit share
December 2013